The developers of Avigan have increased production and announced a Phase III clinical trial testing its efficacy against COVID-19.
List view / Grid view
Filter the results
Cenobamate’s application was based on a global clinical trials programme enrolling over 1,900 adults with uncontrolled focal-onset seizures.
With concerns rising about medicine availability during the global COVID-19 coronavirus pandemic, European Pharmaceutical Review explores how the pharmaceutical supply chain is faring.
The enterprise announced it will donate two million hydroxychloroquine tablets and the same of matched placebo to the multi-national COPCOV study.
A study comparing the V-Go device administering regular human insulin and rapid acting insulin analogues found they were equally effective and safe at controlling blood glucose.
The European Medicines Agency (EMA) has advised consumers on how to recognise registered online pharmacies so they can avoid falsified medications.
The presence of female directors makes boards more likely to report lower-severity defects and faster to recall products with high-severity problems, suggests research.
According to researchers, Zolgensma, made by Novartis, will lead the global spinal muscular atrophy market and generate billions in sales.
According to an outlet, the in-house manufacturing of biopharma products has been threatened by the COVID-19 outbreak, especially in China.
The US FDA has granted approval to BMS for Zeposia, a once daily oral medication for the treatment of relapsing forms of multiple sclerosis.
A summary of the CHMP meeting conclusions, including medicines recommended for approval and indication extension and several safety review findings.
The UK government has reached out to the life sciences sector to ask potential suppliers of COVID-19 testing kits to get in contact.
Mylan and Upjohn (a Pfizer company) revealed they have delayed the transaction due to meeting restrictions and concerns over staff health and safety during the COVID-19 pandemic.
India has stopped exporting the malaria drug Ipca (hydroxychloroquine), despite the FDA lifting its ban on imports due to its potential as a coronavirus treatment.
Gilead Sciences say they are confident they can maintain an expedited regulatory review timeline for remdesivir as a treatment for COVID-19 without Orphan Drug Designation (ODD).